139 related articles for article (PubMed ID: 7736536)
21. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
22. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
[TBL] [Abstract][Full Text] [Related]
24. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
25. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
27. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
Lebtahi R; Le Cloirec J; Houzard C; Daou D; Sobhani I; Sassolas G; Mignon M; Bourguet P; Le Guludec D
J Nucl Med; 2002 Jul; 43(7):889-95. PubMed ID: 12097458
[TBL] [Abstract][Full Text] [Related]
28. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
29. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
[TBL] [Abstract][Full Text] [Related]
30. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
[TBL] [Abstract][Full Text] [Related]
31. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
Duet M; Mundler O; Ajzenberg C; Berolatti B; Chedin P; Duranteau L; Warnet A
Eur J Nucl Med; 1994 Jul; 21(7):647-50. PubMed ID: 7957351
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
34. The role of somatostatin receptor scintigraphy in the management of pituitary tumours.
Moulik PK; Varma TR; Vora JP; Vinjamuri S
Nucl Med Commun; 2002 Feb; 23(2):117-20. PubMed ID: 11891464
[TBL] [Abstract][Full Text] [Related]
35. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
Acosta-Gómez MJ; Muros MA; Llamas-Elvira JM; Ramírez A; Ortega S; Sabatel G; Ramos C; de la Riva-Aguilar A
Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
[TBL] [Abstract][Full Text] [Related]
36. Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors.
Manil L; Edeline V; Lumbroso J; Lequen H; Zucker JM
J Nucl Med; 1996 Jun; 37(6):893-6. PubMed ID: 8683306
[TBL] [Abstract][Full Text] [Related]
37. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
38. 111In-octreotide scintigraphy in oncology.
Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
[TBL] [Abstract][Full Text] [Related]
39. Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization.
DeStephano DB; Lloyd RV; Pike AM; Wilson BS
Am J Pathol; 1984 Sep; 116(3):464-72. PubMed ID: 6089568
[TBL] [Abstract][Full Text] [Related]
40. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]